{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T21:21:27Z","timestamp":1774560087922,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T00:00:00Z","timestamp":1660262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1038\/s41375-022-01677-z","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T14:05:02Z","timestamp":1660313102000},"page":"2408-2417","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia\u2014a Grand Ouest Against Leukemia (GOAL) study"],"prefix":"10.1038","volume":"36","author":[{"given":"Christophe","family":"Desprez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-9257","authenticated-orcid":false,"given":"J\u00e9r\u00e9mie","family":"Riou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-2169","authenticated-orcid":false,"given":"Tony","family":"Marchand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Anne","family":"Couturier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alban","family":"Villate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Baptiste","family":"Mear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaelle","family":"Guillerm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Gyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline","family":"Schmidt-Tanguy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7777-5216","authenticated-orcid":false,"given":"Mathilde","family":"Hunault-Berger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-0824","authenticated-orcid":false,"given":"Corentin","family":"Orvain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,12]]},"reference":[{"key":"1677_CR1","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez\u2010Vizca\u00edno F, Tamayo C, Ramos F, L\u00e1inez\u2010Gonz\u00e1lez D, Serrano\u2010L\u00f3pez J, Barba R et al. Identification of seasonal variation in the diagnosis of acute myeloid leukaemia: a population\u2010based study. Br J Haematol. 2022;198:545\u201355.","DOI":"10.1111\/bjh.18279"},{"key":"1677_CR2","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf \u00c5, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"1677_CR3","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481\u20135.","journal-title":"Blood"},{"key":"1677_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/cncr.22537","volume":"109","author":"A Etienne","year":"2007","unstructured":"Etienne A, Esterni B, Charbonnier A, Mozziconacci M-J, Arnoulet C, Coso D, et al. Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia. Cancer. 2007;109:1376\u201383.","journal-title":"Cancer"},{"key":"1677_CR5","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/bjh.17213","volume":"193","author":"L Hjort Jakobsen","year":"2021","unstructured":"Hjort Jakobsen L, Stidsholt Roug A, Kiesbye \u00d8vlisen A, Werenberg Marcher C, Beier Ommen H, Theilgaard\u2010M\u00f6nch K, et al. Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000\u201316: a Danish population\u2010based study. Br J Haematol. 2021;193:482\u20137.","journal-title":"Br J Haematol"},{"key":"1677_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1182\/blood.2019001728","volume":"134","author":"G Juliusson","year":"2019","unstructured":"Juliusson G, Hagberg O, Lazarevic VL, \u00d6lander E, Antunovic P, Cammenga J, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134:1558\u201361.","journal-title":"Blood"},{"key":"1677_CR7","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41375-021-01503-y","volume":"36","author":"ZLR Kaplan","year":"2022","unstructured":"Kaplan ZLR, van Leeuwen N, Posthuma EFM, Visser O, Huls G, van de Loosdrecht AA, et al. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something. Leukemia. 2022;36:596\u20138.","journal-title":"Leukemia"},{"key":"1677_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126:291\u20139.","journal-title":"Blood"},{"key":"1677_CR9","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"1677_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383:617\u201329.","journal-title":"N Engl J Med"},{"key":"1677_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1182\/blood.2020008812","volume":"138","author":"ML Sorror","year":"2021","unstructured":"Sorror ML, Storer BE, Fathi AT, Brunner A, Gerds AT, Sekeres MA, et al. Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. Blood. 2021;138:387\u2013400.","journal-title":"Blood"},{"key":"1677_CR12","doi-asserted-by":"publisher","first-page":"4163","DOI":"10.1200\/JCO.20.01392","volume":"38","author":"R Palmieri","year":"2020","unstructured":"Palmieri R, Othus M, Halpern AB, Percival M-EM, Godwin CD, Becker PS, et al. Accuracy of SIE\/SIES\/GITMO consensus criteria for unfitness to predict early mortality after intensive chemotherapy in adults with AML or other high-grade myeloid neoplasm. JCO. 2020;38:4163\u201374.","journal-title":"JCO"},{"key":"1677_CR13","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, Ravandi F, Cortes JE, Pierce SA, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. JCO. 2011;29:4417\u201324.","journal-title":"JCO"},{"key":"1677_CR14","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","volume":"3","author":"ML Sorror","year":"2017","unstructured":"Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, et al. Development and validation of a novel acute myeloid leukemia\u2013composite model to estimate risks of mortality. JAMA Oncol. 2017;3:1675.","journal-title":"JAMA Oncol"},{"key":"1677_CR15","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/leu.2012.303","volume":"27","author":"F Ferrara","year":"2013","unstructured":"Ferrara F, Barosi G, Venditti A, Angelucci E, Gobbi M, Pane F, et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia. 2013;27:997\u20139.","journal-title":"Leukemia"},{"key":"1677_CR16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.26395","volume":"97","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97:68\u201378.","journal-title":"Am J Hematol"},{"key":"1677_CR17","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.1200\/JCO.2018.78.7366","volume":"36","author":"A Pigneux","year":"2018","unstructured":"Pigneux A, B\u00e9n\u00e9 MC, Salmi L-R, Dumas P-Y, Delaunay J, Bonmati C, et al. Improved survival by adding lomustine to conventional chemotherapy for elderly patients with AML without unfavorable cytogenetics: results of the LAM-SA 2007 FILO. Trial JCO. 2018;36:3203\u201310.","journal-title":"Trial JCO"},{"key":"1677_CR18","doi-asserted-by":"publisher","first-page":"e481","DOI":"10.1016\/S2352-3026(21)00134-4","volume":"8","author":"JE Lancet","year":"2021","unstructured":"Lancet JE, Uy GL, Newell LF, Lin TL, Ritchie EK, Stuart RK, et al. CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol. 2021;8:e481\u2013e491.","journal-title":"Lancet Haematol"},{"key":"1677_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"1677_CR20","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1677_CR21","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"1677_CR22","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/M14-0698","volume":"162","author":"KGM Moons","year":"2015","unstructured":"Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Ann Intern Med. 2015;162:W1\u201373.","journal-title":"Ann Intern Med"},{"key":"1677_CR23","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1182\/blood.2020010165","volume":"137","author":"M Duchmann","year":"2021","unstructured":"Duchmann M, Micol J-B, Duployez N, Raffoux E, Thomas X, Marolleau J-P, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH -mutated AML: an ALFA study. Blood. 2021;137:2827\u201337.","journal-title":"Blood"},{"key":"1677_CR24","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1182\/blood.2020005524","volume":"137","author":"L Fenwarth","year":"2021","unstructured":"Fenwarth L, Thomas X, de Botton S, Duployez N, Bourhis J-H, Lesieur A, et al. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. Blood. 2021;137:524\u201332.","journal-title":"Blood"},{"key":"1677_CR25","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41375-022-01624-y","volume":"36","author":"C Orvain","year":"2022","unstructured":"Orvain C, Othus M, Johal G, Hunault-Berger M, Appelbaum FR, Walter RB. Evolution of eligibility criteria for non-transplant randomized controlled trials in adults with acute myeloid leukemia. Leukemia. 2022:36;2002\u20138.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01677-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01677-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T19:11:58Z","timestamp":1664478718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01677-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,12]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1677"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01677-z","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,12]]},"assertion":[{"value":"30 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Employment or Leadership Position: none; Consultant or Advisory Role: MHB, Erytech\u00a9; Stock Ownership: none; MHB, Abbvie, Incyte, and Jazz Pharmaceuticals, CO, Novartis; Research Funding: none; Expert Testimony: none; Patents: none; Other Remuneration: none.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}